What question did this study set out to answer?

The research aims to explore the role of oxidative stress in benign prostatic hyperplasia, chronic prostatitis, and prostate cancer.

February 6, 2026Open Access

Parameters of Oxidative Stress in Patients With Benign Prostate Hyperplasia, Chronic Prostatitis, and Prostate Cancer

Key Points

The research aims to explore the role of oxidative stress in benign prostatic hyperplasia, chronic prostatitis, and prostate cancer.
Included 17 patients with chronic prostatitis, 10 with benign prostatic hyperplasia, and 15 with prostate cancer.
Collected serum and surgical tissue samples for analysis.
Measured oxidative stress markers such as thiobarbituric acid-reactive substances and advanced oxidation protein products.
Determined xanthine oxidase activity in plasma and tissue homogenates.
Serum concentrations of TBARS and AOPP were significantly higher in BPH and CP patients compared to healthy controls (p < 0.001).
Xanthine oxidase activity was also markedly increased in BPH and CP groups.
In prostate cancer tissue, both TBARS and AOPP concentrations and XO activity were significantly elevated compared to non-tumor tissue (p < 0.001).
Elevated oxidative stress indicators suggest a potential link between inflammation and prostate cancer development.

Abstract

p class=cvGsUA direction-ltr align-justify para-style-body style=text-align: justify;span class=aGcMg font-feature-liga-off font-feature-clig-off font-feature-calt-off text-decoration-none text-strikethrough-noneBenign prostatic hyperplasia (BPH), chronic prostatitis (CP), and prostate cancer (PC) are frequently occurring conditions that affect the prostate gland, with overlapping clinical features and potentially shared pathogenetic mechanisms. A growing body of research indicates that oxidative stress (OS) is a critical factor in both the onset and advancement of these disorders. Xanthine oxidase (XO) is a known enzymatic source of reactive oxygen species (ROS), however, its involvement in prostate disease pathogenesis remains underexplored. /spanspan class=aGcMg font-feature-liga-off font-feature-clig-off font-feature-calt-off text-decoration-none text-strikethrough-noneThe study included 17 patients with CP, 10 with BPH, and 15 with PC. Ten healthy individuals served as controls. Serum samples were collected for BPH and CP groups, while PC samples were obtained from surgical tissues. OS was assessed by measuring thiobarbituric acid-reactive substances (TBARS) and advanced oxidation protein products (AOPP). XO activity was determined spectrophotometrically in plasma and tissue homogenates. /spanspan class=aGcMg font-feature-liga-off font-feature-clig-off font-feature-calt-off text-decoration-none text-strikethrough-noneSerum concentrations of TBARS and AOPP were markedly higher in individuals diagnosed with BPH and CP relative to those in the healthy control group (p lt; 0. 001). Similarly, XO activity was markedly increased in these groups. In PC tissue, both TBARS and AOPP concentrations, as well as XO activity, were significantly higher than in non-tumor prostate tissue (p lt; 0. 001), indicating local OS and enzymatic ROS production. /spanspan class=aGcMg font-feature-liga-off font-feature-clig-off font-feature-calt-off text-decoration-none text-strikethrough-noneThese findings confirm that systemic and tissue-level OS is elevated in BPH, CP, and PC. XO may represent a shared mechanism linking inflammation and carcinogenesis. The study supports further investigation into the therapeutic potential of antioxidants and XO inhibitors as adjunct strategies in prostate disease management. /span/p

Read Full Paperexternally

Ask AI

Helpful

Bookmark

View Full Paper